Clinical Study Results, Acquisitions, Upcoming Earnings Schedules, and New Drug Technologies- Research Report on Abbott, St. Jude Medical, Cigna, Edwards Lifesciences, and Novogen PR Newswire NEW YORK, October 18, 2013 NEW YORK, October 18, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Abbott Laboratories(NYSE: ABT), St. Jude Medical, Inc.(NYSE: STJ), Cigna Corporation(NYSE: CI), Edwards Lifesciences Corporation(NYSE: EW), and Novogen Limited (ADR)(NASDAQ: NVGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Abbott Laboratories Research Report On October 11, 2013, Abbott Laboratories (Abbott) issued a press release stating that a study - conducted by researchers at the University of Southern California, The Children's Hospital of Philadelphia, Harvard Medical School, Massachusetts General Hospital, and Precision Health Economics, and supported by the Company - found that the use of oral nutritional supplements provided to pediatric patients during hospitalization was associated with a decrease in length of stay of 14.8% and a decrease in hospital stay costs of $1,768 per patient. Abbott stated that the 11-year retrospective study (2000-2010) was analyzed using the Premier Research Database, which contains data on more than half a million hospitalized pediatric patients aged 2 to 8 years. Robert H. Miller, Ph.D., Divisional Vice President, Global Research & Development and Scientific Affairs for Abbott Nutrition, stated, "Through its leadership in nutrition health economics and outcomes research, Abbott is demonstrating the potential that nutritional intervention can have for the health of children and adult patients, and the cost savings for hospitals." The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/05c1_ABT] St. Jude Medical, Inc. Research Report On October 14, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced that it has completed the acquisition of Nanostim Inc. (Nanostim), a privately-owned developer of miniaturized, leadless pacemakers. The Company stated that this acquisition adds the world's first and only leadless pacemaker to its product portfolio andconcludes a two-year partnership between the Companies during which St. Jude Medical invested in and collaborated with Nanostim throughout its product development and commercialization initiatives. St. Jude Medical informed that Nanostim leadless pacemaker recently received CE Mark approval and will be available soon in select European markets. In addition, the US Food and Drug Administration (FDA) granted it conditional approval for its Investigational Device Exemption (IDE) application and pivotal clinical trial protocol to begin evaluating Nanostim leadless technology in the United States. The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b338_STJ] Cigna Corporation Research Report On October 15, 2013, Cigna Corporation (Cigna) and Brown &Toland Physicians (Brown &Toland) announced that they have expanded their collaborative accountable care initiative to include additional Brown &Toland doctors and locations. Cigna said that Brown & Toland's East Bay affiliate, Alta Bates Medical Group (ABMG), began participating in the program, giving Cigna access to 327 additional physicians at numerous locations in Oakland, Berkeley and other places in East Bay, as of October 1, 2013. Cigna said that collaborative accountable care is the Company's approach to accomplish the same population health goals as Accountable Care Organizations (ACOs), i.e. the "triple aim" of improved health, affordability, and patient experience. Commenting on the expanded collaboration, Richard Fish, Brown & Toland's CEO, said, "Our ACO model continues to show good results for different patient populations and our care managers and the entire care coordination team is ready to work with our East Bay doctors to proactively implement programs and services designed to help members achieve better health." The Full Research Report on Cigna Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7307_CI] Edwards Lifesciences Corporation Research Report On October 14, 2013, Edwards Lifesciences Corporation (Edwards Lifesciences) announced that it will report its Q3 2013 financial and operating results on October 28, 2013. The Company informed that it will host a conference call at 10:00 a.m. ET on the same date to discuss its results. Edwards Lifesciences informed that the call can be accessed via live or archived webcast through the "Investor Relations" section of the Company website. On July 25, 2013, the Company had stated that it is expecting full-year 2013 sales in the range of $2.0 billion to $2.1 billion, and EPS (excluding special items) in the range of $3.00 to $3.10. The Full Research Report on Edwards Lifesciences Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/48b8_EW] Novogen Limited (ADR) Research Report On October 9, 2013, Novogen Limited (ADR) (Novogen) announced that it has acquired a new drug technology that will be developed as a potentially major class of cancer drugs known as anti-tropomyosins(anti-Tms). The Company stated that anti-Tm drugs will join its pipeline of super-benzopyran drugs, including Trilexium and related analogs. According to Novogen, the target of anti-Tm drugs is the protein Tm5NM1, an integral part of the microfilament component of the cytoskeleton of the cell. Novogenstated that inhibition of TM5NM1 blocks the ability of a cancer cell to function and to divide. Novogen stated that it has acquired the technology from Genscreen, a private Australian biotechnology company in a transaction based on a royalty payment of product sales, with no upfront or milestone fees. The Full Research Report on Novogen Limited (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c60b_NVGN] EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by NamrataMaheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.AnalystsCorner.com SOURCE Analysts' Corner Contact: Media Contact: Joe Thomas, +1-310-496-8071 (North America)
Clinical Study Results, Acquisitions, Upcoming Earnings Schedules, and New Drug Technologies- Research Report on Abbott, St.